U.S. NUCLEAR REGULATORY COMMISSION

Amendment No. 20

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	In accordance with the letter dated February 16, 2011,
1. Nanticoke Memorial Hospital	3. License number 07-17618-01 is amended in its entirety to read as follows:
2. 801 Middleford Road Seaford, Delaware 19973	4. Expiration date June 30, 2013
	5. Docket No. 030-13060 Reference No.

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As needed
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As needed
C. Any byproduct material permitted by 10 CFR 35.400	C. Sealed Sources (See Condition 12)	C. 1000 millicuries
D. Any byproduct material permitted by 10 CFR 35.500	D. Sealed Sources (DuPont Merck Model NES 8426)	D. 36 millicuries per source and 500 millicuries total
E. Any byproduct material permitted by 10 CFR 31.11	E. Prepackaged Kits	E. 5 millicuries

9. Authorized use:

A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
B. Any imaging and localization study permitted by 10 CFR 35.200.
C. Any manual brachytherapy procedure permitted by 10 CFR 35.400, for which the patient can be released under the provisions of 10 CFR 35.75.
D. Diagnostic medical use of sealed sources permitted by 10 CFR 35.500 in compatible devices registered pursuant to 10 CFR 30.32(g).
E. In vitro studies.

MATERIALS LICENSE SUPPLEMENTARY SHEET

License Number
07-17618-01

Docket or Reference Number
030-13060

Amendment No. 20

CONDITIONS

10. Licensed material may be used or stored only at the licensee's facilities located at 801 Middleford Road, Seaford, Delaware.

11. The Radiation Safety Officer for this license is Andrew Vennos, M.D.

12. Sealed sources authorized pursuant to Item 7.C. of the license shall be in accordance with the following table:

Radionuclide	Source Model Number	Maximum Activity per Source
Iodine 125	Amersham Health/Medi-Physics, Inc. Model 6711 (OncoSeed)	270 millicuries
	Amersham Health/Medi-Physics, Inc. Model 6733 (EchoSeed)	71.2 millicuries
	North American Scientific, Inc. Model MED 3631	25 millicuries
	Best Medical International, Inc. Model 2300 Series	110 millicuries
	BEBIG Model 125.S06	100 millicuries
	Mills Biopharmaceuticals, LLC Model I-125 SL and I-125 SH	150 millicuries
	IsoAid, LLC Model IAI-125A	10 millicuries
	Bard Brachytherapy, Inc. Model Model STM 1251	15 millicuries
	DRAXIMAGE, LLC Model LS-1 (manufactured by Draxis Specialty Pharmaceuticals, Inc.)	75 millicuries
	Implant Sciences Corporation Model 3500	7.5 millicuries
	IsoStar Texas, Inc. Model IS-125 Series	10 millicuries

MATERIALS LICENSE SUPPLEMENTARY SHEET

License Number 07-17618-01

Docket or Reference Number 030-13060

Amendment No. 20

Radionuclide	Source Model Number	Maximum Activity per Source
Iodine 125	International Brachytherapy SA Model 1251L	6.5 millicuries
	Syncor Pharmaceuticals, Inc. Model BT-125-1	6 millicuries
	Amersham/Medi-Physics, Inc. Model 6702	195 millicuries
Palladium 103	Theragenics Corporation TheraSeed Model 200	100 millicuries

13. Licensed material is only authorized for use by, or under the supervision of:

A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.

B. The following individuals are authorized users for medical use as indicated:

Authorized Users	Material and Use
Andrew Vennos, M.D.	35.100; 35.200; 35.500; In vitro studies
Vincenzo De Masi, M.D.	35.400
Manoj Jain, M.D.	35.400
Robert Corcoran, M.D.	35.100; 35.200
Phillip Hugo, M.D.	35.100; 35.200
Gerard J. F. Hogan, M.D.	35.100; 35.200
Thomas Riccio, M.D.	35.100; 35.200
Mario Todorov, M.D.	35.100; 35.200
Alexander Zito, M.D.	35.100; 35.200
David Chung, M.D.	35.100; 35.200

MATERIALS LICENSE SUPPLEMENTARY SHEET

License Number
07-17618-01

Docket or Reference Number
030-13060

Amendment No. 20

Authorized Users	Material and Use
Assen Todorov, M.D.	35.100; 35.200
William Reid, M.D.	35.100; 35.200
Marvin E. Nielsen, M.D.	35.100; 35.200
Peter Libby, M.D.	35.100; 35.200
Simmi Chawla, M.D.	35.100; 35.200
Michael Marks, M.D.	35.100; 35.200

14. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."

15. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.

MATERIALS LICENSE SUPPLEMENTARY SHEET

License Number
07-17618-01

Docket or Reference Number
030-13060

Amendment No. 20

16. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

A. Application dated March 27, 2003 [ML030970692]
B. Letter dated June 4, 2003 [ML031671344]
C. Letter dated February 5, 2007 [ML070650669]
D. Letter dated March 23, 2010 [ML100880446]

For the U.S. Nuclear Regulatory Commission

Date March 30, 2011

By ***Original signed by Tara L. Weidner***

Tara L. Weidner
Medical Branch
Division of Nuclear Materials Safety
Region I
King of Prussia, Pennsylvania 19406